Safety and Efficacy Study of Acthar in Subjects With ARDS

Summary

This study is being performed to evaluate the potential efficacy and safety of Acthar as a treatment for moderate-severe Acute Respiratory Distress Syndrome (ARDS). Approximately 210 subjects will be randomized to 1 of 6 possible treatment groups in a 3:2:3:2:3:2 ratio. Study medication (SM) will be administered via subcutaneous (SC) injection for 4 weeks using a blinded gradually tapering regimen, and subjects will be followed for 60 days post-randomization.

Timeline

Start

2014-08

Primary completion

2016-08

Completion

2016-08

Outcome

Outcome not reported

Stopped: “A company decision was made not to proceed with the study.”

Drugs

Indications